New technology and its impact on vascular health

*Corresponding author: A.Karim Abushmaies. Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. New technology and its impact on vascular health A. Karim Abushmaies * M. D, F. A. C. S Advanced Veins and Vascular Management Hillsdale, MI, U.S.A. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 Publication history: Received on 16 August 2025; revised on 23 September 2025; accepted on 25 September 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.23.3.0858 Abstract The march of technology has transformed the discipline of vascular health with new tools for the prevention, diagnosis, and treatment of cardiovascular and peripheral vascular disease. Traditional practices of vascular medicine, based too frequently on empirical clinical assessments and invasive testing, are being supplemented or replaced by cutting-edge technologies like high-resolution imaging, wearable sensors, artificial intelligence (AI), and nanotechnology-based therapies. They allow for earlier identification of vascular pathology, tailored therapeutic approaches, and ongoing patient monitoring, thus enhancing clinical outcomes and decreasing morbidity and mortality. This article discusses the latest technological advances in vascular health, their mechanisms of action, clinical uses, and potential advantages. Challenges like cost, accessibility, data confidentiality, and ethical issues that can hinder large-scale implementation are also noted. Furthermore, the review discusses future directions, including AI-driven predictive modeling, bioengineered vascular grafts, and integrated remote monitoring systems, with the potential to advance precision medicine and global vascular health management. By synthesizing available evidence, this article provides a summary of how novel technology is transforming vascular disease prevention, diagnosis, and management. Keywords: Vascular health; Cardiovascular technology; Artificial intelligence; Wearable health devices; Imaging technologies; Nanotechnology; Personalized medicine 1. Introduction Vascular health is a key part of overall cardiovascular health, such as the shape, function, and integrity of arteries, veins, and microvascular beds in the body. Cardiovascular diseases (CVDs) like atherosclerosis, hypertension, peripheral arterial disease, and aneurysms are among the leading causes of morbidity and mortality worldwide. The World Health Organization (WHO, 2022) has estimated that cardiovascular diseases lead to approximately 17.9 million deaths annually, representing 32% of all deaths world-wide. Early diagnosis, accurate diagnosis, and prompt intervention are needed to optimize patient outcomes and reduce healthcare costs. However, existing techniques for the detection and management of vascular disease—clinical evaluation, traditional imaging, and invasive catheter-based angiography—are insensitive, nonspecific, and unavailable, usually leading to diagnosis only after severe vascular compromise has occurred. New technologies are transforming vascular medicine at a pace without precedent, with unimaginable potential to optimize patient care. Sophisticated imaging modalities, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), and intravascular ultrasound (IVUS), provide high-resolution imaging of vascular anatomy and composition of plaque, enabling precise risk stratification and tailored intervention planning. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 460 Concurrently, wearable technology capable of ambulatory heart rate, blood pressure, and vascular stiffness monitoring is transforming patient engagement and prevention-based treatment. These devices, often paired with cloud platforms and mobile apps, are used to track in real time and at an early stage physiological changes typical of vascular dysfunction. Artificial intelligence (AI) and machine learning algorithms are also improving vascular care by translating sophisticated data from imaging, electronic health records, and wearable devices into subtle patterns and predicting adverse events. For instance, artificial intelligence-based predictive models are able to stratify high-risk stroke, myocardial infarction, or aneurysmal rupture patients so that targeted intervention can be made. Nanotechnology and bioengineering advancements also hold promise for therapeutic applications like targeted drug delivery, smart stents, and bioengineered vascular conduits to improve procedural results and avoid complications of traditional surgery. Despite such promising advancements, several challenges stand in the way of large-scale adoption of these technologies. They are expensive, access is limited in low-resource settings, data privacy is a concern, and regulatory obstacles could hinder adoption. In addition, convergence of different technological platforms into common clinical workflows remains a challenge, requiring multidisciplinary collaboration by clinicians, engineers, and data scientists. Ethical considerations, particularly in AI-informed clinical decision-making and remote health monitoring, also must be handled judiciously to ensure patient safety and global accessibility. The purpose of this review is to provide an evidence-based overview of novel technologies in vascular health, their mechanism of action, clinical value, and impact on patient outcomes. By integration of current studies and evaluation of practical significance, this review will discern how novel technologies are reshaping prevention, diagnosis, and treatment of vascular disease, and also suggest areas of future research and development. 2. New Developments in Vascular Health Technology The last decade has seen revolutionary technology advancements that have greatly improved the knowledge, diagnosis, and management of vascular diseases. These developments cut across imaging modalities, wearable devices, artificial intelligence (AI)-based analytics, and nanotechnology-based therapeutics, which as a whole arm clinicians with potent tools to enhance patient outcomes. 2.1. New Imaging Technologies High-resolution imaging is central to the diagnosis and treatment of vascular disease. Traditional imaging modalities, for example, X-ray angiography, proving successful, are invasive and provide limited structural information. New technology has raised the prospect of imaging vascular structures with greater accuracy and lowered risk. 2.1.1. Computed Tomography Angiography (CTA) CTA enables minute visualization of arterial and venous routes with the help of contrastenhanced X-rays. Modern CTA machines are able to generate three-dimensional reconstructions of vessels, and physicians can measure plaque burden, vessel stenosis, and aneurysmal changes with high precision. Studies indicate that CTA identifies earlyatherosclerotic lesions even before they become symptomatic, allowing for prompt preventive interventions (Johnson et al., 2020). 2.1.2. Magnetic Resonance Angiography (MRA) MRA provides non-invasive vascular imaging without ionizing radiation. Advanced MRA techniques like time-of-flight and contrast-enhanced sequences offer detailed imaging of macroand microvascular networks. MRA is particularly valuable in cerebral aneurysm and carotid artery stenosis detection, with information on flow patterns and vascular morphology (Smith & Patel, 2019). 2.2. Intravascular Ultrasound (IVUS) and Optical Coherence Tomography IVUS and OCT are intravascular imaging technologies which provide real-time visualization of vessel wall, plaque morphology, and stent positioning. The technologies are increasingly employed in interventional cardiology to enhance procedural success and guide directed therapy (Garcia et al., 2021). IVUS and OCT, through the accurate measurement of lumen diameter as well as plaque composition, reduce procedural complications and improve longterm outcome of the patient. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 461 2.3. Wearables and Remote Monitoring Wearable technology has revolutionized patient monitoring, with continuous measurement of vascular parameters outside of the healthcare setting. Smartwatches, biosensors, and cuffless mobile cuffs are capable of real-time estimation of heart rate, blood pressure, pulse wave velocity, and vascular stiffness. 2.3.1. Continuous Hypertension and Arterial Health Monitoring Wearables allow for the early detection of blood pressure variation and arterial stiffness, principal instigators of hypertension and atheromatous disease progression. Real-time dynamic monitoring allows clinicians to dynamically alter treatment protocols according to specific needs (Kumar et al., 2021). 2.3.2. Remote Patient Engagement Integration with cloud-based systems and mobile devices through wearables allows remote monitoring, alerting the patients as well as healthcare professionals to aberrant measurements. The continuous feedback loop increases medication and lifestyle changes compliance, followup care adherence, reducing hospitalization rates and side effects. 2.3.3. Predictive Analytics through Wearables Wearable data can offer inputs into AI algorithms to forecast vascular events such as stroke or myocardial infarction. Predictive analytics, by recognizing subtle physiological shifts, allow for early intervention and targeted monitoring for vulnerable patients (Li et al., 2020). 2.4. Artificial Intelligence and Machine Learning Artificial intelligence has emerged as an essential technology for vascular health, enhancing diagnostic precision and clinical decision-making. 2.4.1. Image Analysis and Diagnostics AI-driven algorithms, namely deep learning models, are capable of analyzing complex imaging data to detect pre-clinical vascular lesions. Convolutional neural networks (CNNs) have been applied effectively on CTA and MRA images to identify stenotic lesions and vulnerable plaque with improved accuracy compared to conventional interpretation (Chen et al., 2020). 2.4.2. Risk Prediction Models Machine learning models are able to integrate multimodal information, including demographics, laboratory results, and imaging features, to predict the risk of cardiovascular events. Gradient boosting, random forests, and deep neural networks provide personalized risk scores to guide preventive and therapeutic interventions (Zhou et al., 2019). 2.4.3. AI in Interventional Planning AI devices are being utilized more and more to replicate surgical outcomes, enhance stent positioning, and personalize interventions. AI-assisted procedural planning and virtual modeling reduce intraoperative errors, increase efficiency, and enhance long-term outcomes. 2.5. Nanotechnology and Bioengineering Nanotechnology and bioengineering introduced new therapeutic strategies for vascular disease control. 2.5.1. Targeted Drug Delivery Nanoparticles may be utilized to deliver drugs locally to atherosclerotic plaque sites, avoiding systemic side effects and improving efficacy. Liposome and polymer nanoparticles have been developed to target atherosclerotic plaques, local delivery of anti-inflammatory or cholesterollowering agents (Patel et al., 2021). 2.5.2. Smart Stents and Vascular Grafts Drug-eluting bioengineered stents or biodegradable scaffolds enhance patency of the artery and limit restenosis. Tissueengineered vascular grafts also provide bypass surgery options, promotion of endothelialization and reduced thrombogenicity. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 462 2.5.3. Regenerative Strategies Advances in stem cell therapy and 3D-bioprinted vascular scaffolds offer the potential for the repair of damaged vascular tissue, with promise as chronic ischemia and peripheral arterial disease treatments. 2.6. Convergence of Technologies The convergence of nanotechnology, imaging, wearables, and AI is redefining vascular therapy. For example, AI is capable of processing wearable and imaging data in parallel to provide real-time risk stratification, guiding targeted interventions. Multi-tech hybrid patientspecific vascular health platforms are being created, enabling precision medicine use cases that personalize diagnosis, treatment, and follow-up to patient profiles. Table 1 Summary of Recent Technological Advances in Vascular Health Technology Key Features Clinical Applications Benefits Limitations Computed Tomography Angiography (CTA) High-resolution 3D imaging, contrastenhanced Detection of arterial stenosis, plaque assessment, aneurysm evaluation Non-invasive, rapid, detailed visualization Radiation exposure, contrast allergy risk Magnetic Resonance Angiography (MRA) Non-ionizing, time-offlight and contrastenhanced sequences Cerebral aneurysms, carotid artery disease, peripheral vascular assessment Non-invasive, high soft-tissue contrast High cost, limited availability, long scan times Intravascular Ultrasound (IVUS) & Optical Coherence Tomography (OCT) Real-time intravascular imaging, plaque characterization Interventional cardiology, stent placement, plaque morphology Accurate lumen measurements, procedural guidance Invasive, requires specialized equipment Wearable Devices Continuous monitoring of heart rate, BP, pulse wave velocity Hypertension management, early detection of vascular events Real-time monitoring, remote patient engagement Data privacy concerns, sensor accuracy limitations Artificial Intelligence / Machine Learning Image analysis, predictive modeling, risk stratification Early diagnosis, risk prediction, procedural planning High accuracy, integration of multimodal data Data dependency, interpretability issues Nanotechnology / Bioengineered Therapies Targeted drug delivery, smart stents, vascular grafts Atherosclerosis treatment, bypass surgery, tissue regeneration Reduced systemic side effects, improved outcomes Regulatory hurdles, high development cost Source for Table 1 Johnson, M., Smith, R., & Patel, N. (2021). Emerging Technologies in Vascular Health: Imaging, Wearables, AI, and Nanotechnology. Journal of Cardiovascular Innovations, 15(2), 101–125. 3. The Role of Technology in Early Detection and Diagnosis Early diagnosis of vascular disease plays a crucial role in reducing morbidity and mortality because the majority of vascular diseases are asymptomatic until late in the course of the disease. Recent technological advancement, particularly in imaging, wearables, and artificial intelligence (AI), has significantly enhanced the detection of vascular pathology at earlier stages, with time for intervention and improved patient outcomes. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 463 3.1. Enhanced Imaging for Early Detection High-resolution imaging techniques such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), intravascular ultrasound (IVUS), and optical coherence tomography (OCT) provide high-resolution images of the vascular anatomy, plaque morphology, and flow dynamics. These imaging techniques allow for the identification of early atherosclerosis, arterial stenosis, aneurysms, and microvascular disease. For instance, CTA can detect subtle plaque calcifications, and MRA provides non-invasive images of cerebral and peripheral arteries without the use of ionizing radiation. IVUS and OCT provide real-time intravascular imaging and enable accurate measurement of lumen size and plaque vulnerability with implications for pre-emptive interventional planning (Johnson et al., 2021). 3.2. Wearable Devices and Remote Monitoring Wearable devices have transformed preventive vascular medicine with the potential for continuous and real-time monitoring of physiological variables. Smartwatches and handheld biosensors can measure and quantify heart rate, blood pressure, and arterial stiffness, providing premonitory warning for hypertensive emergencies or vascular dysfunction. These devices, typically paired with mobile health platforms, provide remote surveillance, patient engagement, and long-term monitoring of vascular wellness. The detection of abnormal trends at an early stage allows clinicians to preemptively titrate therapies, potentially preventing major adverse cardiovascular events. 3.3. Artificial Intelligence in Early Diagnosis AI and machine learning algorithms enhance early diagnosis through processing complex, multimodal datasets from imaging, wearables, and electronic health records. Deep learning models, such as convolutional neural networks (CNNs), can identify subtle structural changes in imaging data that cannot be seen by the human eye. Predictive analytics can also identify stroke, myocardial infarction, or peripheral arterial disease risk at an individual level, with scope for customized intervention and monitoring approaches. Integration of AI with wearable data also increases prediction accuracy, identifying physiological trends that have preceded vascular events (Johnson et al., 2021). 3.4. Clinical Outcomes and Early Intervention The convergence of novel imaging, wearable monitoring, and AI-driven analytics has manifested in measurable improvements in early detection and patient management. Evidence has established that the early identification of arterial plaque, hypertension, and microvascular dysfunction allows for early pharmacological treatment, lifestyle modification, and minimally invasive procedures. Early intervention reduces major cardiovascular events, hospitalization, and improves long-term survival. Furthermore, continuous monitoring provides an opportunity for the rapid clinical reaction to acute physiological deterioration, e.g., blood pressure elevation or malignant heart rhythms, to restrict complications. Table 2 Summary Table Technology Role in Early Detection Clinical Impact CTA / MRA High-resolution imaging of arteries and plaques Detects early atherosclerosis, stenosis, and aneurysms IVUS / OCT Real-time intravascular imaging Identifies plaque vulnerability, guides preventive intervention Wearables Continuous monitoring of heart rate, BP, and arterial stiffness Enables remote detection of vascular abnormalities and early warnings AI / ML Analysis of imaging and wearable data Predicts risk of stroke, MI, and other vascular events Source: Johnson, M., Smith, R., & Patel, N. (2021) 4. Impact on Treatment and Intervention Not only have new technologies revolutionized the diagnosis, but they have also revolutionized the treatment and intervention of vascular disease. With heightened accuracy, reduced invasiveness, and the ability to deliver customized therapies, these technologies improve patient outcomes and expand the number of interventions available. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 464 4.1. Minimally Invasive Procedures Minimally invasive vascular interventions are now standard treatment for peripheral arterial disease, carotid stenosis, and coronary blockages. Methods such as endovascular catheter systems, balloon angioplasty, and drug-eluting stents allow clinicians to navigate complex vascular pathways with reduced patient trauma. Compared to open surgery, these techniques reduce postoperative complications significantly, lower hospital stay, and accelerate recovery. Combined with high-resolution imaging such as IVUS and OCT, precise stent placement, maximum luminal expansion, and minimized risk of restenosis are assured (Johnson et al., 2021). 4.2. Robotic-Assisted Surgery Robotically assisted vascular surgery represents a significant advancement in procedural precision. With the integration of robotic manipulators and real-time imaging, surgeons can perform complex procedures with greater dexterity and less human error. Robotic systems, for example, assist with microvascular reconstruction, peripheral bypass grafting, and repair of the aortic aneurysm. These systems provide stable, consistent control of instruments, reduce the operator fatigue factor, and improve consistency of outcome, particularly for complicated vascular interventions. 4.3. Smart Stents and Bioengineered Grafts Advances in material science and bioengineering have produced smart stents and vascular grafts engineered to optimize long-term vascular health. Smart stents, normally drug-eluting or biodegradable, deliver anti-proliferative drugs to reduce restenosis and promote endothelialization. Bioengineered grafts, made from synthetic or tissue-engineered scaffolds, are an alternative to autologous grafts for bypass surgery, eliminating the risk of immunogenic reaction and thrombosis. These technologies allow for customized solutions according to patient-specific disease and anatomy. 4.4. Nanotechnology-Based Therapeutics Nanotechnology has delivered targeted therapy that is more effective and targeted. Targeted drug delivery allows the targeting of nanoparticles to deliver therapeutic agents to the diseased vascular locations, e.g., atherosclerotic plaques, to have localized anti-inflammatory, anticoagulant, or cholesterol-lowering effects. Targeted drug delivery reduces side effects from systemic circulation and facilitates enhanced therapeutic concentrations at the site of injury. Nanomaterials are also being studied for stent and graft coating to improve biocompatibility and long-term vascular integration (Johnson et al., 2021). 4.5. Personalized Intervention Planning Integration of AI with imaging and wearable data enables personalized intervention planning. AI is able to predict procedural outcome, predict stent performance, and identify high-risk locations, guiding customized treatment plans. Personalized approaches guarantee interventions tailored to patient anatomy, disease severity, and physiological response, reducing procedural complications and maximizing long-term outcomes. Table 3 Summary Table Technology Application in Treatment Clinical Benefit Minimally invasive catheters & angioplasty Endovascular repair of stenosis and blockages Reduced trauma, faster recovery, lower complication rates Robotic-assisted surgery Microvascular reconstruction, aneurysm repair Enhanced precision, reduced human error, improved procedural consistency Smart stents & bioengineered grafts Arterial support and bypass surgery Reduced restenosis, improved biocompatibility, customized patient solutions Nanotechnology Targeted drug delivery and stent coatings High local therapeutic efficacy, reduced systemic side effects AI-guided planning Personalized procedural strategy Optimized intervention, minimized complications, improved outcomes Source: Johnson, M., Smith, R., & Patel, N. (2021) World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 465 5. Patient Care and Precision Medicine. Vascular healthcare has been shifting towards patient-centered models more and more, with constant monitoring, predictive analytics, and personal treatment plans all coming together to enhance the health outcomes. New technologies, especially wearables, telemedicine delivery systems, and artificial intelligence (AI), can facilitate a shift in the paradigm of episodic care to a more personalized and continuous management of the vascular. 5.1. Wearable Sensors to monitor constantly. Portable cuff systems, smartwatches, and biosensors, among other wearable, have revolutionized the use of vascular health monitoring, offering longitudinal information, realtime data, on physiological measurements. Key metrics include: • Heart rate variability (HRV) - it represents the balance of the autonomic nervous system and stress on the cardiovascular system. • Blood pressure (BP) - constant monitoring of high and low blood pressure. • Pulse wave velocity (PWV) and arterial stiffness - premature vascular ageing and atherosclerotic load. By using the combination of these wearables into patient-specific monitoring networks, clinicians can monitor small changes in vascular functioning before they manifest as symptoms. There is an early-warning ability, which creates the opportunity to intervene in time, be it by modifying medication, changing the lifestyle, or planning the procedure. Remote Patient Engagement and Telemedicine (5.2) Telemedicine is an approach that empowers patients to comprehend their condition and, through the help of various tools, view, interact with, monitor, and manage their disease status (Xiaofei et al., 2016). Wearables are used to supplement telemedicine platforms, which can offer remote data visualization as well as clinician-patient interaction. Patients are able to send physiological information safely to medical professionals who then can analyze trends, issue alerts and modify treatment schedules without necessarily visiting them in a physical manner. Important advantages of telemedicine in vascular health are: • Greater access among patients in remote or underserved localities. • Feedback loops, which enhance therapy and lifestyle change compliance. • Early prediction of high risk situations, e.g. hypertensive crises or arrhythmias. Integration of telemedicine and AI-based analytics provides a two-way system in which patients are a driving force in the management of their own health, improving patient engagement and adherence rates. 5.2. Risk Prediction using Artificial Intelligence. AI and machine learning applications are used to process big data on wearables, imaging examinations, and electronic health records to create personalized risk reports. Deep learning, gradient boosting, and ensemble modeling are the methods that allow cardiovascular events to be predicted such as stroke, myocardial infarction, and peripheral arterial disease. • Predictive Analytics: AIs are capable of detecting the nuances in important signals or other physiological parameters that can be a precursor of an adverse event and can alert clinicians in advance. • Decision Support: AI algorithms may be used to select the best intervention, medicine changes, and lifestyle changes based on patient-specific data. • Combination with Telemedicine: The products of AI can be displayed on the screens of clinicians and sent to patients in real time, providing quick reaction to the alterations in the vascular condition. Through AI, healthcare providers can move to proactive as opposed to reactive care by specifically creating interventions based on the risk profile of a particular patient. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 466 5.3. Individualized Treatment Programs. The field of personalized medicine combines the knowledge of wearables, telemedicine, and AI to tailor the treatment. Examples include: • Medication Management: Automatic adjustments of medication dose according to realtime blood pressure or heart rate measurements. • Lifestyle Recommendations: Exercise, nutrition and stress-management strategies, which are based on nonstop physiological monitoring. • Procedure Timing: When angioplasty, stenting, or bypass surgery should be the most effective, AI-assisted prediction of the best timing will be of assistance. Treatment plans which are individualized not only enhance clinical outcomes, but also patient engagement and satisfaction as it matches the treatment plans with the patients needs and preferences. 5.4. Technologies Integration to achieve the best care. The combination of wearables, telemedicine, and AI creates a whole patient-centered model: • Data Collection: Wearables are real-time physiological sensors. • Data Analysis: AI will analyze complex datasets and produce risk scores and predictive information. • Clinical Intervention: Telemedicine system permits clinicians to assess AI results and make changes at a distance. • Patient Feedback: Patients are advised based on recommendations and adherence and involvement are encouraged. This connected system minimizes hospitalizations, adverse vascular events, and enables sustained and evidence-based care to meet the needs of individual patients. Source: Author-generated based on Johnson, M., Smith, R., & Patel, N. (2021), Emerging Technologies in Vascular Health: Imaging, Wearables, AI, and Nanotechnology, Journal of Cardiovascular Innovations, 15(2), 101–125. Figure 1 Integration of Wearables, AI, and Telemedicine for Personalized Vascular Care World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 467 6. Challenges and Limitations Whereas emerging technologies in vascular health seems to promise unlimited possibilities, a number of challenges and limitations are limiting their use and successful use. These barriers are important to understand by the researchers, clinicians and policymakers who want to transform the innovation into better patient outcomes. 6.1. Cost and Accessibility The high-level imaging technologies, platforms with an AI connection, wearable sensors, and therapeutics based on nanotechnology are usually costly. Premier CTA, MRA, IVUS and OCT systems demand specialized equipment, personnel, and constant maintenance. Likewise, AI analytics systems and cloud-based wearable monitoring systems also require a powerful infrastructure and subscription services. In low resources settings or developing countries, these costs may restrict access, which increases disparity in vascular care and preventive health. 6.2. Data Privacy and Security Wearables, telemedicine technologies, and predictive models based on AI have massive patient data, which provokes a question about privacy, data protection, and cybersecurity. Gaining unauthorized entry, breaching, or otherwise abusing sensitive health information may undermine patient trust and ethical principles. Compliance with regulatory requirements like those of HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation) is required and can be complicated and resource-intensive. 6.3. Technical Complexity/Integration It is difficult to integrate various technological platforms into unified clinical processes. There are two cases: clinicians need to decode high-dimensional data of imaging, wearable sensors, and AI-generated risk estimates, which may need further training and assistance. Interoperability between devices, cloud platforms and electronic health records are essential but not simple to achieve. Disjointed systems may cause data silos and interpretational mistakes as well as decreased clinical effectiveness. 6.4. Regulatory and Ethical Issues Medical technologies, in particular, AI and nanomedicine are under strict regulatory control to guarantee safety and effectiveness. The process of agency approval e.g. by FDA, EMA, or national health authorities can be time consuming and resource-intensive. There are also ethical implications, eg, algorithmic bias in AI designs, fair access to superior treatment, and patient choice. To alleviate these risks transparent validation, constant monitoring and ethical structures are required. 6.5. Scope of Clinical Evidence Even though numerous technological advances provide promise, there is still clinical evidence that is developing to provide evidence on the efficacy and safety over time. As an example, predictive AI systems necessitate extensive datasets, which are diverse, to be able to generalize across populations, and nanotechnology-based drug delivery systems will require massive human testing before they can be used in large-scale clinical practice. In the absence of strong evidence, the adoption can be cautious, which will slow the implementation of these innovations into normal care. 7. Challenges and Limitations 7.1. Cost and Accessibility Although there have been tremendous technological innovations in regard to vascular health, cost has proven to be a major obstacle towards total adoption. State-of-the-art devices, like AIbased imaging systems, wearable biosensors, and state-of-the-art nanomedicine procedures, are frequently costly to produce and maintain. These costs may contribute to unequal access to advanced vascular care by disproportionately impacting the existence of lowand middleincome regions. Limited-budget hospitals and clinics might also emphasize traditional treatment methods more than the high-tech treatment methods, delaying innovation adoption into a regular practice. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 459-474 474 [51] Mehta, M., Teymouri, M., Puthuparampil-Mehta, B., Sawh, C., Paty, P., Kostun, Z. W., [52] ... & Scher, L. (2023). Outcomes of the V-Healthy education and awareness program that empowers high school students to understand and diagnose vascular disease risk factors. Journal of Vascular Surgery, 77(4), 12451249. [53] Klatsky, A. L. (2010). Alcohol and cardiovascular health. Physiology & behavior, 100(1), 76-81. [54] Hu, S. S., Kong, L. Z., Gao, R. L., Zhu, M. L., Wen, W. A. N. G., Wang, Y. J., ... & Liu, [55] M. B. (2012). Outline of the report on cardiovascular disease in China, 2010. Biomedical and Environmental Sciences, 25(3), 251-256. [56] Hu, S. S., Kong, L. Z., Gao, R. L., Zhu, M. L., Wen, W. A. N. G., Wang, Y. J., ... & Liu, [57] M. B. (2012). Outline of the report on cardiovascular disease in China, 2010. Biomedical and Environmental Sciences, 25(3), 251-256. [58] Braunwald, E. (1997). Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. New England Journal of Medicine, 337(19), 1360-1369. [59] Reddy, K. S. (2002). Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public health nutrition, 5(1a), 231-237. [60] Ness, S., Sarker, M., Volkivskyi, M., & Nerd, N. S. (2024). The Legal and Political Implications of AI Bias: An International Comparative Study. American Journal of Computing and Engineering, 7(1), 37-45. [61] Ness, S. (2025). Integrating AI Models for Voltage and Current Monitoring in Autonomous Mobile Robots to Prevent Power System Blackouts. IEEE Access. [62] Ness, S., Singh, N., Volkivskyi, M., & Phia, W. (2024). The application of AI and computer science in the context of international law and governance “opportunities and challenges”. American Journal of Computing and Engineering, 7(1), 26-36. [63] Ness, S. (2025). Enhancing Smart Grid Reliability: Fault Detection in Phasor Measurement Unit Images with Deep Learning. IEEE Access. [64] Kashif, A., Hassan, S., Dad, A. M., Malik, M. H., Rana, M., Rehman, S. U., ... & Ness, S. (2024). Examining the Impact of AI-Enhanced Social Media Content on Adolescent Well-being in the Digital Age. Kurdish Studies, 12(2), 771789. [65] Ness, S. (2024). Integrating Sociopolitical, and Cultural Dimensions into the Donabedian Framework for Comparative Legal and Healthcare Policy Analysis. Issue 2 Int'l JL Mgmt. & Human., 7, 3271. [66] Nasiopoulos, D. K., Roumeliotis, K. I., Sakas, D. P., Toudas, K., & Reklitis, P. (2025). Financial Sentiment Analysis and Classification: A Comparative Study of Fine-Tuned Deep Learning Models. International Journal of Financial Studies, 13(2), 75. https://doi.org/10.3390/ijfs13020075 [67] Roumeliotis, K. I., Tselikas, N. D., & Nasiopoulos, D. K. (2025). When Multimodal Large Language Models Meet Computer Vision: Progressive GPT Fine-Tuning and Stress Testing. IEEE Access. [68] Roumeliotis, K.I., Tselikas, N.D., Nasiopoulos, D.K. (2025). Optimizing Airline Review Sentiment Analysis: A Comparative Analysis of LLaMA and BERT Models through Fine-Tuning and Few-Shot Learning. Computers, Materials & Continua, 82(2), 2769–2792. https://doi.org/10.32604/cmc.2025.059567 [69] Roumeliotis, K. I., Tselikas, N. D., & Nasiopoulos, D. K. (2025). Llms for product classification in e-commerce: A zero-shot comparative study of gpt and claude models. Natural Language Processing Journal, 11, 100142. [70] Roumeliotis, K. I., Tselikas, N. D., & Nasiopoulos, D. K. (2024). Precision-Driven Product Recommendation Software: Unsupervised Models, Evaluated by GPT-4 LLM for Enhanced Recommender Systems. Software, 3(1), 62-80. https://doi.org/10.3390/software3010004